AIM
AGRX

Acrospire Investment Management’s Agile Therapeutics AGRX Stock Holding History

Acrospire Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed -$22K – 2636
2017
Q1 		$22K Buy
+3
New +$15.1K 0.02% 1578

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Acrospire Investment Management's AGRX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Agile Therapeutics (AGRX) in Q2 2017, closing a stake of 3 shares — an estimated $22K sold.

Acrospire Investment Management first reported a position in AGRX in Q1 2017 and held it in 1 quarter. The position peaked at $22K in Q1 2017. 41 funds tracked by Wall St. Rank hold AGRX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Agile Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3 Agile Therapeutics shares in Q2 2017, an estimated $22K.
  • Acrospire Investment Management first reported a position in Agile Therapeutics in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Agile Therapeutics position peaked at $22K in Q1 2017.
  • 41 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.